TNF

Hyphens Pharma licenses Wynzora® Cream for ASEAN countries from MC2 Therapeutics

Retrieved on: 
星期二, 三月 12, 2024
Cream, TNF, EUR, Psoriasis, Agreement, Inflammation, Patient, PAD, Dermatology, MC2, Skin, Gold, Comorbidity, Safety, Good, Pharmaceutical industry

SINGAPORE, March 12, 2024 /PRNewswire/ -- Hyphens Pharma International Limited ("Hyphens Pharma", or the "Company", and together with its subsidiaries, the "Group"), Singapore's leading specialty pharmaceutical and consumer healthcare group, is pleased to announce that its subsidiary, Hyphens Pharma Pte.

Key Points: 
  • SINGAPORE, March 12, 2024 /PRNewswire/ -- Hyphens Pharma International Limited ("Hyphens Pharma", or the "Company", and together with its subsidiaries, the "Group"), Singapore's leading specialty pharmaceutical and consumer healthcare group, is pleased to announce that its subsidiary, Hyphens Pharma Pte.
  • Ltd., has entered into an exclusive license, supply and commercialisation agreement (the "Agreement") with MC2 Therapeutics ("MC2") for the exclusive rights to register and commercialise Wynzora® Cream and all future product extensions and/or improvements for the topical treatment of plaque psoriasis in the 10 ASEAN countries.
  • Wynzora® Cream ( www.wynzora.com ), is a leading topical treatment for plaque psoriasis, including scalp psoriasis in adults.
  • "Hyphens Pharma is a leading specialty pharma company focused on the commercialisation of innovative pharmaceutical products in the ASEAN region.

Hyphens Pharma licenses Wynzora® Cream for ASEAN countries from MC2 Therapeutics

Retrieved on: 
星期二, 三月 12, 2024
Cream, TNF, EUR, Psoriasis, Agreement, Inflammation, Patient, PAD, Dermatology, MC2, Skin, Gold, Comorbidity, Safety, Good, Pharmaceutical industry

SINGAPORE, March 12, 2024 /PRNewswire/ -- Hyphens Pharma International Limited ("Hyphens Pharma", or the "Company", and together with its subsidiaries, the "Group"), Singapore's leading specialty pharmaceutical and consumer healthcare group, is pleased to announce that its subsidiary, Hyphens Pharma Pte.

Key Points: 
  • SINGAPORE, March 12, 2024 /PRNewswire/ -- Hyphens Pharma International Limited ("Hyphens Pharma", or the "Company", and together with its subsidiaries, the "Group"), Singapore's leading specialty pharmaceutical and consumer healthcare group, is pleased to announce that its subsidiary, Hyphens Pharma Pte.
  • Ltd., has entered into an exclusive license, supply and commercialisation agreement (the "Agreement") with MC2 Therapeutics ("MC2") for the exclusive rights to register and commercialise Wynzora® Cream and all future product extensions and/or improvements for the topical treatment of plaque psoriasis in the 10 ASEAN countries.
  • Wynzora® Cream ( www.wynzora.com ), is a leading topical treatment for plaque psoriasis, including scalp psoriasis in adults.
  • "Hyphens Pharma is a leading specialty pharma company focused on the commercialisation of innovative pharmaceutical products in the ASEAN region.

MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day

Retrieved on: 
星期日, 三月 10, 2024
Psoriatic arthritis, ACR, Doctor of Philosophy, Adalimumab, Skin, American College, Webcast, Moonlake, HS, Patient, Psoriasis, VELA, MMSc, ARGO, MIRA, EDT, Physician, Inflammation, Safety, Prognosis, Clinical trial, Ankylosing spondylitis, TNF, IL-17A, MDA, American Academy, EMA, Medical college, FDA, Food, Steroid, Prevalence, AAD, Event, Joint, PASI, Hidradenitis suppurativa, PSA, PPP, Disease, Porokeratosis, Medicine, Pharmaceutical industry

In addition, by week 24, over 80% and 60% of patients treated with sonelokimab achieved Psoriasis Area Severity Index (PASI) 90 and 100, respectively.

Key Points: 
  • In addition, by week 24, over 80% and 60% of patients treated with sonelokimab achieved Psoriasis Area Severity Index (PASI) 90 and 100, respectively.
  • Treatment with sonelokimab resulted in unprecedented improvements in composite scores that reflect responses in different domains simultaneously.
  • In all composite scores, sonelokimab showed 16-29 percentage point differences to the reference adalimumab arm, comparatively higher to competitors using the same reference arm.
  • The discontinuation rate of the second part of ARGO remained low at 5%, in line with other sonelokimab trials.

ACTG Presents Study at CROI Elucidating Mechanism of CMV on Aging-Related Pathways in HIV

Retrieved on: 
星期一, 三月 4, 2024
Infection, Chairperson, Bangladesh Technical Education Board, Diabetes, CMV, Metabolism, Merck, Cancer, Endothelial dysfunction, Fungal infection, NIAID, CROI, Inflammation, Blood, IL-6, Ageing, ACTG, Splenic infarction, Risk, Conference, Cytomegalovirus, University, ART, Biomarker, Merck & Co., University of California, UM1, Insulin resistance, Poster, Letermovir, Probability, Atherosclerosis, Plasma, TNF, HIV, University of North Carolina, Immune system, Brain

CMV is a chronic and usually asymptomatic virus carried by 60 percent of adults in the general population and more than 95 percent of people living with HIV.

Key Points: 
  • CMV is a chronic and usually asymptomatic virus carried by 60 percent of adults in the general population and more than 95 percent of people living with HIV.
  • Prior to the availability of effective antiretroviral therapy (ART) for HIV, CMV caused life-threatening infections in the eyes, brain, and gut in people with compromised immune systems due to advanced HIV.
  • “Investigators have found associations between CMV and heart disease, cancer, and other aging-related complications among people living with HIV,” said ACTG Chair Judith Currier, M.D., M.Sc., University of California, Los Angeles.
  • ACTG is led by Dr. Currier and Joseph J. Eron, M.D., University of North Carolina (ACTG Vice-Chair).

Charting New Paths: Non-TNF's Evolving in Rheumatoid Arthritis Market

Retrieved on: 
星期五, 二月 23, 2024
Therapy, Rheumatology, Rheumatoid arthritis, Physician, Rituximab, Adalimumab, JAK, Health, Patient, MOA, TNF, Research, Pharmaceutical industry

As demand for improved outcomes rises, it is vital for manufacturers to understand the top drivers catalyzing switching decisions in the well-established, yet continually evolving, RA landscape.

Key Points: 
  • As demand for improved outcomes rises, it is vital for manufacturers to understand the top drivers catalyzing switching decisions in the well-established, yet continually evolving, RA landscape.
  • Ongoing research from Spherix Global Insight’s Patient Chart Dynamix™: Rheumatoid Arthritis (US) service, marking its eighth year of tracking the US RA switch market, sheds light on these key treatment trends and leading opportunities for drug manufacturers.
  • While “TNF cycling” remains common, accounting for about one-third of all switches, this trend has been declining since 2017.
  • Brands that excel in these areas are well-positioned to capture market share and reshape treatment approaches.

United States HUMIRA Market Analysis, Size, Forecast, and Insights Report, 2019-2023 and 2024-2032 - ResearchAndMarkets.com

Retrieved on: 
星期五, 三月 1, 2024
Pharmaceutical, Health, Clinical Trials, Psoriatic arthritis, Ulcerative colitis, JIA, Crohn's disease, Psoriasis, Ankylosing spondylitis, Uveitis, Adalimumab, SWOT, Juvenile idiopathic arthritis, UC, AbbVie, Rheumatoid arthritis, Hidradenitis suppurativa, Clinical trial, HS, TNF, Research, Pharmaceutical industry

The "US HUMIRA Market Size, Forecast, and Market Insight - 2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US HUMIRA Market Size, Forecast, and Market Insight - 2032" report has been added to ResearchAndMarkets.com's offering.
  • This report provides comprehensive insights about HUMIRA for autoimmune uveitis in the US.
  • Further, it also consists of future market assessments inclusive of the HUMIRA market forecast analysis for autoimmune uveitis in the US, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in autoimmune uveitis.
  • What are the other emerging products available and how are these giving competition to HUMIRA for autoimmune uveitis?

Organon Announces HADLIMA™ (adalimumab-bwwd) Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National Formulary

Retrieved on: 
星期二, 二月 20, 2024
FDA, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Certification, Sepsis, Psoriasis, Adolescence, Infection, Adalimumab, Hospital, Intuition, Public sector, TB, Risk, Safety, Arthritis, Rheumatoid arthritis, Hidradenitis suppurativa, Death, Autoimmunity, Patient, Lymphoma, Tuberculosis, Malignancy, TNF, OGN, Pharmaceutical industry

Organon (NYSE: OGN), a global healthcare company with a dedicated commitment to biosimilars, announced that the US Department of Veterans Affairs (VA) has exclusively selected HADLIMA in replacement of HUMIRA (adalimumab) for the VA National Formulary.

Key Points: 
  • Organon (NYSE: OGN), a global healthcare company with a dedicated commitment to biosimilars, announced that the US Department of Veterans Affairs (VA) has exclusively selected HADLIMA in replacement of HUMIRA (adalimumab) for the VA National Formulary.
  • "America’s veterans deserve access to quality medicines at a lower cost.
  • “We applaud the VA for its leadership in championing biosimilars and including all three of Organon’s biosimilars available in the US on its formulary."
  • HADLIMA was launched in the US to offer patients a more affordable option without compromising on safety and efficacy.

Teva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV-‘574) Antibody at the 2024 ECCO Annual Meeting

Retrieved on: 
星期二, 二月 20, 2024
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Other Health, SNY, SAN, Ulcerative colitis, Crohn's disease, TEVA, Inflammation, European, Teva, Teva Pharmaceuticals, Asthma, Gastrointestinal tract, Safety, UC, Immunoglobulin G, Inflammatory bowel disease, Patient, Fibrosis, TL1A, IBD, Medication, TNF, ECCO, Pharmaceutical industry

“These results from the first-in-human trials of anti-TL1A (TEV-’574) are exciting because they show that it effectively engages with the TL1A target, supports its safety profile and is well-tolerated.

Key Points: 
  • “These results from the first-in-human trials of anti-TL1A (TEV-’574) are exciting because they show that it effectively engages with the TL1A target, supports its safety profile and is well-tolerated.
  • “We are currently investigating the efficacy and safety of anti-TL1A (TEV-’574) in IBD through the RELIEVE UCCD Phase 2 trial, which features an innovative and efficient basket study design allowing the inclusion of patients with either type of IBD (ulcerative colitis and Crohn’s disease).
  • Each company will equally share the development costs globally and net profits and losses in major markets, with other markets subject to a royalty arrangement, and Sanofi will lead the development of the Phase 3 program.
  • Teva will lead commercialization of the product in Europe, Israel and specified other countries, and Sanofi will lead commercialization in North America, Japan, other parts of Asia and the rest of the world.

EnLiSense CCM Advances Validation of Real-Time IBD Inflammatory Biomarker Monitoring with Two Recent Peer-Reviewed Longitudinal Studies

Retrieved on: 
星期四, 二月 15, 2024
Hardware, Health Technology, Data Management, Other Health, Technology, Professional Services, Biometrics, Medical Devices, Genetics, Artificial Intelligence, Wearables, Mobile Technology, Biotechnology, Science, Data Analytics, Research, Health, Biosensor, Digital health, Ulcerative colitis, Senior, Doctor of Philosophy, Translation, Hasso Plattner Institute, Moses Austin, MD, Professor, Inflammation, Blood, IL-6, Quality of life, Bioelectronics, Gastrointestinal tract, Trial of the century, Scientific Reports, Management, University, Perspiration, CRP, Clinical, Inflammatory bowel disease, Patient, Biological engineering, Optimism, IBD, Conditional sentence, TNF, Endoscopy, National Institutes of Health, Medical imaging

Our innovative IBD Aware device offers the first solution for continuous, non-invasive monitoring of IBD through the power of sweat-sensing technology.

Key Points: 
  • Our innovative IBD Aware device offers the first solution for continuous, non-invasive monitoring of IBD through the power of sweat-sensing technology.
  • EnLiSense's journey reaches a significant milestone with over half a million human biomarker readings, underscoring the extensive validation of our technology.
  • These readings provide crucial data points, enhancing the precision and trustworthiness of inflammatory biomarker monitoring.
  • The studies involved measuring inflammation markers CRP, TNF-α, and IL-6 in subjects' blood and sweat continuously in subjects with and without IBD.

INmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Retrieved on: 
星期一, 二月 12, 2024
TNF, Conference

Boca Raton, Florida, Feb. 12, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer’s disease (AD) with XProTM (XPro1595; pegipanermin), a dominant-negative inhibitor of soluble TNF, announced today that RJ Tesi, M.D., Chief Executive Officer, and David Moss, Chief Financial Officer, will present a corporate update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference being held virtually from February 13-14, 2024.

Key Points: 
  • Boca Raton, Florida, Feb. 12, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer’s disease (AD) with XProTM (XPro1595; pegipanermin), a dominant-negative inhibitor of soluble TNF, announced today that RJ Tesi, M.D., Chief Executive Officer, and David Moss, Chief Financial Officer, will present a corporate update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference being held virtually from February 13-14, 2024.
  • Dr. Tesi and Mr. Moss will be available for one-on-one meetings throughout the conference.
  • Please contact your Oppenheimer salesperson to schedule one-on-one meetings with the management team.